Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma gains EU Marketing Authorization for Trabectedin
Details : EVER Pharma has received the EU-wide marketing authorization of Trabectedin EVER Pharma, which is available in 0.25mg and 1mg vial sizes for treating advanced soft tissue sarcoma and ovarian cancer.
Product Name : Trabectedin EVER Pharma
Product Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2024
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Pharmamar Receives US$10 Million Milestone Payment from Janssen
Details : Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cance...
Product Name : Yondelis
Product Type : Small molecule
Upfront Cash : Undisclosed
November 06, 2023
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Valeo Pharma Commences Yondelis® Commercialization in Canada
Details : Yondelis (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, that acts a DNA inhibitor. It is indicated for the treatment of of patients with...
Product Name : Yondelis
Product Type : Small molecule
Upfront Cash : Not Applicable
November 06, 2023
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Global Sarcoma Therapy Now Approved for New Zealand Patients
Details : Yondelis (trabectedin) binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix triggering a cascade of events like DNA repair pathways, resulting in ...
Product Name : Yondelis
Product Type : Small molecule
Upfront Cash : Not Applicable
February 17, 2023
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Pharmamar Receives US$10 Million Milestone Payment from Janssen
Details : Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cance...
Product Name : Yondelis
Product Type : Small molecule
Upfront Cash : Undisclosed
December 12, 2022
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Natco Pharma Gets Tentative Approval for Yondelis Generic
Details : Yondelis-Generic (trabectedin) is a DNA inhibitor, small molecule drug candidate. It is being developed for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who rece...
Product Name : Yondelis-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
August 18, 2022
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
GLOBAL Sarcoma Therapy Now Approved for Australian Patients
Details : The Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin), marketed by Specialised Therapeutics, "for the treatment of patients with unresectable or metastatic liposarcoma or lei...
Product Name : Yondelis
Product Type : Small molecule
Upfront Cash : Not Applicable
April 23, 2021
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : STADA Arzneimittel
Deal Size : Undisclosed
Deal Type : Agreement
PharmaMar and STADA Sign Agreement to Commercialize Yondelis® (trabectedin) in the MENA Region
Details : PharmaMar has granted to STADA a license to market the Yondelis® (trabectedin) marine-derived cancer treatment in 15 Middle East-North Africa countries. Yondelis® is marketed in several MENA countries f...
Product Name : Yondelis
Product Type : Small molecule
Upfront Cash : Undisclosed
November 17, 2020
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : STADA Arzneimittel
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Onko Kocsel Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
PharmaMar Signs a New Agreement with Onko to Commercialize Yondelis® in Turkey
Details : Trabectedin is currently provided by Janssen to patients in Turkey for the treatment of Soft Tissue Sarcoma and, through this license, Onko will also pursue regulatory approval for the indication of relap...
Product Name : Yondelis
Product Type : Small molecule
Upfront Cash : Undisclosed
August 10, 2020
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Onko Kocsel Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Adium Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Pharmamar Signs a New Agreement with Adium Pharma S.A. to Commercialize Yondelis® in Latin Americ...
Details : Through agreement, Adium will be able to commercialize the marine-derived anticancer drug Yondelis (trabectedin), which is used in the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Product Name : Yondelis
Product Type : Small molecule
Upfront Cash : Undisclosed
July 27, 2020
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Adium Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?